NIAID VIROLOGY QUALITY ASSURANCE (VQA) COVID-19
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 75N93019C00015-P00001-9999-2
Grant search
Key facts
Disease
COVID-19Start & end year
20202021Known Financial Commitments (USD)
$668,265Funder
National Institutes of Health (NIH)Principal Investigator
THOMAS DENNYResearch Location
United States of AmericaLead Research Institution
DUKE UNIVERSITYResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Diagnostics
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
The purpose of the NIAID Virology Quality Assurance (VQA) program is to provide a comprehensive quality assessment program for virologic assays for HIV, and other viral pathogens, performed on samples from subjects enrolled in NIAID-sponsored multisite clinical studies. The VQA program ensures the validity and inter- and intra-laboratory comparability of virologic laboratory data obtained from NIAID-supported clinical trials and HIV natural history studies by providing laboratories with proficiency testing panels and real-time assay run controls and analyzing proficiency panel and assay run data from each laboratory. The VQA program also implements standards of performance for existing and state-of-the-art new virologic assays, develops and tests biostatistical methods relating to the assays, and acquires, tests, stores and dispenses quality control materials and reagents. Support under this project is for SARS-CoV-2 (COVID-19) virologic assay quality assurance activities.